Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Hematologic Diseases 1

Interventions

Brentuximab Vedotin 17 fludarabine 9 Cyclophosphamide 9 dacetuzumab 6 Lenalidomide 6 Bortezomib 6 ruxolitinib 5 fludarabine phosphate 5 Rituximab 5 Melphalan 5 Dexamethasone 4 Busulfan 4 lintuzumab 3 Whole-Body Irradiation 3 Mycophenolic Acid 3 Imatinib Mesylate 3 Granulocyte Colony-Stimulating Factor 3 Doxorubicin 3 Calcium Dobesilate 3 Azacitidine 3 vosaroxin 2 spartalizumab 2 ponatinib 2 nilotinib 2 Vincristine 2 Thiotepa 2 Tacrolimus 2 Sugars 2 Stem Cell Transplantation 2 Rifampin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Hematologic Diseases × CHR 2845 × Clear all

NCT00820508 2011-11-28

CHR-2845-001

Chroma Therapeutics

Phase 1 Completed

Hematologic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡